Hepatocellular carcinoma - From macroscopy to molecular pathology;A hepatocellularis carcinoma - A makroszkópiától a molekuláris patológiáig

Orvosi Hetilap

Volumn 151, Issue 24, 2010, Pages 982-989

  Schaff, Zsuzsa ^a   Kovalszky, Ilona ^a   Lotz, Gábor ^a   Kiss, András ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; GLYPICAN 3; MICRORNA; SURVIVIN;

HISTOPATHOLOGY; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; REVIEW; WORLD HEALTH ORGANIZATION;

ANIMALS; BIOPSY; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; PATHOLOGY, MOLECULAR; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953225117     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2010.28875     Document Type: Review

References (47)

1. Mendizabal, M., Reddy, K. R.: Current management of hepatocellular carcinoma. Med. Clin. N. Am., 2009, 93, 885-900.
2. Takayama, T., Makuuchi, M., Kojiro, M. és mtsai: Early hepatocellular carcinoma: Pathology, imaging, and therapy. Ann. Surg. Oncol., 2008, 15, 972-978.
3. Hussain, K., El-Serag, H. B.: Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma. Minerva Gastroenterol. Dietol., 2009, 55, 123-138.
4. El-Serag, H. B., Rudolph, K. L.: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132, 2557-2576.
5. Llovet, J. M., Di Bisceglie, A. M., Bruix, J. és mtsai: Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl. Cancer Inst., 2008, 100, 698-711.
6. Bolondi, L., Sofi a, S., Siringo, S. és mtsai: Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut, 2001, 48, 251-259.
7. Velazquez, R. F., Rodriguez, M., Navascues, C. A. és mtsai: Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology, 2003, 37, 520-527. (Pubitemid 36258772)
8. International Consensus Group for Hepatocellular Neoplasia: Pathologic diagnosis of early hepatocellular carcinoma: A report of the International Consensus Group for Hepatocellular Neoplasia. Hepatology, 2009, 49, 658-664.
9. Mínguez, B., Tovar, V., Chiang, D. és mtsai: Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr. Opin. Gastroenterol., 2009, 25, 186-194.
10. Llovet, J. M., Bruix, J.: Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 2008, 48, 1312-1327.
11. Aravalli, R. N., Steer, C. J., Cressman, E. N. K.: Molecular mechanisms of hepatocellular carcinoma. Hepatology, 2008, 48, 2047-2063.
12. Tanaka, S., Arii, S.: Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci., 2009, 100, 1-8.
13. Villanueva, A., Toffanin, S., Llovet, J. M.: Linking molecular classifi cation of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr. Opin. Oncol., 2008, 20, 444-453.
14. Desmet, V. J.: East-West pathology agreement on precancerous liver lesions and early hepatocellular carcinoma. Hepatology, 2009, 49, 355-357.
15. International Working Party: Terminology of nodular hepatocellular lesions. Hepatology, 1995, 22, 983-993.
16. Roncalli, M., Borzio, M., Di Tommaso, L.: Hepatocellular dysplastic nodules. Hepatol. Res., 2007, 37, S125-S134.
17. Kojiro, M., Roskams, T.: Early hepatocellular carcinoma and dysplastic nodules. Semin. Liver Dis., 2005, 25, 133-142.
18. Nascimento, C., Caroli-Bottino, A., Paschoal, J. és mtsa: Vascular immunohistochemical markers: contributions to hepatocellular nodule diagnosis in explanted livers. Transplant. Proc., 2009, 41, 4211-4213.
19. Ohashi, M., Wakai, T., Korita, P. V. és mtsai: Histological evaluation of intracapsular venous invasion for discrimination between portal and hepatic venous invasion in hepatocellular carcinoma. J. Gastroenterol. Hepatol., 2010, 25, 143-149.
20. Lee, J.-S., Heo, J., Libbrecht, L. és mtsai: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med., 2006, 12, 410-416.
21. Kim, H., Park, C., Han, K. H. és mtsai: Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J. Hepatol., 2004, 40, 298-304.
22. Torbenson, M.: Review of the clinicopathologic features of fibrolamellar carcinoma. Adv. Anat. Pathol., 2007, 14, 217-223.
23. Liu, S., Chan, K. W., Wang, G. és mtsa: Fibrolamellar hepatocellular carcinoma. Am. J. Gastroenterol., 2009, 104, 2617-2624.
24. El-Serag, H. B., Davila, J. A.: Is fi brolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology, 2004, 39, 798-803.
25. Chen, X-M.: MicroRNA signatures in liver diseases. World J. Gastro enterol., 2009, 15, 1665-1672.
26. Bala, S., Marcos, M., Szabo, Gy.: Emerging role of microRNAs in liver diseases. World J. Gastroenterol., 2009, 15, 5633-5640.
27. Lee, J. S., Chu, I. S., Heo, J. és mtsai: Classifi cation and prediction of survival in hepatocellular carcinoma by gene expression profi ling. Hepatology, 2004, 40, 667-676.
28. Wennerberg, A. E., Nalesnik, M. A., Coleman, W. B.: Hepatocyte paraffi n 1: A monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am. J. Pathol., 1993, 143, 1050-1054.
29. Minervini, M. I., Demetris, A. J., Lee, R. G. és mtsai: Utilization of hepatocyte-specifi c antibody in the immunocytochemical evaluation of liver tumors. Mod. Pathol., 1997, 10, 686-692.
30. Kandil, D. H., Cooper, K.: Glypican-3. A novel diagnostic marker for hepatocellular carcinoma and more. Adv. Anat. Pathol., 2009, 16, 125-129.
31. Shirakawa, H., Suzuki, H., Shimomura, M. és mtsai: Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci., 2009, 100, 1403-1407.
32. Libbrecht, L., Severi, T., Cassiman, D. és mtsai: Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am. J. Surg. Pathol., 2006, 30, 1405-1411.
33. Nassar, A., Cohen, C., Siddiqui, M. T.: Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fi ne-needle aspiration biopsies. Diagn. Cytopathol., 2009, 37, 629-635.
34. Di Tommaso, L., Franchi, G., Park, Y. N. és mtsai: Diagnostic value of HSP70, glypican 3 and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology, 2007, 45, 725-734.
35. Christa, L., Simon, M. T., Flinois, J. P. és mtsai: Overexpression of glutamine synthetase in human primary liver cancer. Gastroenterology, 1994, 106, 1312-1320.
36. Tátrai P., Dudás J., Batmunkh E. és mtsai: Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma. Lab. Invest., 2006, 86, 1149-1160.
37. Batmunkh, E., Tátrai P., Szabó E. és mtsai: Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma. Human Pathol., 2007, 38, 1508-1515.
38. Tátrai P., Egedi K., Somorácz Á. és mtsai: Quantitative and qualitative alterations of heparan sulfate in fi brogenic liver diseases and hepatocellular cancer. J. Histochem. Cytochem., 2010, 58, 429-441.
39. Szabó, E., Lódi, Cs., Korpos, E. és mtsai: Expression of matrilin-2 in oval cells during rat liver regeneration. Matrix Biol., 2007, 26, 554-560.
40. Szabó, E., Korpos, É., Batmunkh, E. és mtsai: Expression of matrilin-2 in liver cirrhosis and hepatocellular carcinoma. Pathol. Oncol. Res., 2008, 14, 15-22.
41. Lódi, Cs., Szabó, E., Holczbauer, Á. és mtsai: Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas. Mod. Pathol., 2006, 19, 460-469.
42. Kiss, A., Holczbauer, Á., Kaposi Novák, P. és mtsai: Increased expression of claudin-1 and claudin-7 in liver cirrhosis and hepatocellular carcinoma. XXVII International Congress of the International Academy of Pathology, Athens, Greece, October 12-17, 2008.
43. Maturen, K. E., Nghiem, H. V., Marrero, J. A. és mtsai: Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique. AJR, 2006, 187, 1184-1187.
44. Farazi, P. A., DePinho, R. A.: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer, 2006, 6, 674-687.
45. Thorgeirsson, S. S., Grisham, J. W.: Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet., 2002, 31, 339-346.
46. Villanueva, A., Newell, P., Chiang, D. Y. és mtsai: Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis., 2007, 27, 55-76.
47. Barba, G., Harper, F., Harada, T. és mtsai: Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc. Natl. Acad. Sci. USA, 1997, 94, 1200-1205.